Keyphrases
Venous Thromboembolism
82%
Multiple Myeloma
71%
Anticoagulation
35%
Thromboprophylaxis
33%
Direct Oral Anticoagulants
26%
Confidence Interval
24%
American Society of Hematology
23%
United States Veterans
23%
Thrombosis
22%
Diffuse Large B-cell Lymphoma (DLBCL)
20%
Patients with COVID-19
20%
Living Guidelines
19%
Enzalutamide
19%
Abiraterone
19%
Malignancy
17%
Apixaban
17%
Hemostasis
16%
Patients with Cancer
16%
In Cancer
15%
Bleeding
14%
Retrospective Cohort Study
14%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
14%
Cancer-associated Venous Thromboembolism
13%
COVID-19
13%
Warfarin
12%
Dose Reduction
12%
Chemotherapy
12%
Venous Thromboembolism Risk
12%
Overall Survival
11%
Coronavirus Disease (COVID)
11%
Hematological Malignancies
10%
High Risk
10%
Grading of Recommendations
10%
Evaluation Assessment
10%
Assessment Development
10%
Comorbid Diseases
10%
Major Bleeding
10%
Comparative Effectiveness
10%
Venous Thromboembolism Treatment
10%
Hospitalization
9%
Cancer-associated Thrombosis
9%
Frailty
9%
Statins
9%
Reduced Dose
9%
Patients with Obesity
9%
Critically Ill Patients
9%
Venus
9%
Veterans Health Administration
9%
US Veterans
8%
Risk Prediction Model
8%
Medicine and Dentistry
Venous Thromboembolism
100%
Multiple Myeloma
49%
COVID-19
38%
Thrombosis
37%
Anticoagulation
36%
Thromboprophylaxis
33%
Hematology
23%
Malignant Neoplasm
23%
Direct Oral Anticoagulant
20%
Clinician
20%
Bleeding
20%
Cancer
17%
Blood Stasis
16%
Diffuse Large B-Cell Lymphoma
14%
Apixaban
14%
Odds Ratio
11%
Cancer Treatment
11%
Drug Dose Reduction
10%
Major Bleeding
10%
Hematologic Malignancy
10%
Retrospective Cohort Study
10%
Thrombocytopenia
9%
CHOP
9%
Pancreas Cancer
9%
Sarcopenia
9%
Critical Illness
8%
Hazard Ratio
8%
Disease
8%
Randomized Controlled Trial
6%
Acute Disease
6%
Overall Survival
6%
Risk Stratification
6%
Lenalidomide
6%
Low Molecular Weight Heparin
6%
Rivaroxaban
6%
Health Outcomes
5%
Dexamethasone
5%
Phlebothrombosis
5%
Randomized Clinical Trial
5%
Pancreas Adenocarcinoma
5%
International Classification of Diseases
5%
Health Care
5%
Secondary Prevention
5%
Immunomodulatory Drug
5%
Placebo
5%
Antithrombotic
5%
Oncology
5%
Pharmacology, Toxicology and Pharmaceutical Science
Venous Thromboembolism
57%
Multiple Myeloma
49%
Thrombosis
25%
Malignant Neoplasm
20%
Chemotherapy
20%
Bleeding
19%
Enzalutamide
19%
Abiraterone
19%
Diffuse Large B Cell Lymphoma
15%
Direct Oral Anticoagulant
15%
Disease
14%
Cohort Study
14%
Warfarin
14%
Prostate Cancer
14%
Apixaban
11%
Hematologic Malignancy
10%
Frailty
9%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
9%
Overall Survival
7%
Lenalidomide
6%
Dexamethasone
5%
Infection
5%